1. Home
  2. IQ vs NRIX Comparison

IQ vs NRIX Comparison

Compare IQ & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iQIYI Inc.

IQ

iQIYI Inc.

N/A

Current Price

$1.29

Market Cap

2.0B

ML Signal

N/A

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

N/A

Current Price

$15.62

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IQ
NRIX
Founded
2009
2009
Country
China
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
IQ
NRIX
Price
$1.29
$15.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
13
Target Price
$2.91
$29.46
AVG Volume (30 Days)
11.0M
690.4K
Earning Date
01-01-0001
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,987,000.00
Revenue This Year
$1.57
N/A
Revenue Next Year
$3.79
$26.32
P/E Ratio
N/A
N/A
Revenue Growth
N/A
99.31
52 Week Low
$1.32
$8.18
52 Week High
$2.76
$22.50

Technical Indicators

Market Signals
Indicator
IQ
NRIX
Relative Strength Index (RSI) 19.50 45.34
Support Level N/A $15.62
Resistance Level $2.16 $16.47
Average True Range (ATR) 0.08 0.80
MACD -0.03 0.09
Stochastic Oscillator 0.90 57.14

Price Performance

Historical Comparison
IQ
NRIX

About IQ iQIYI Inc.

Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: